UnitedHealth Group Inc (UNH) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

UnitedHealth Group Inc (UNH)

411.04

+2.52 (0.62%)

as of Jun 15, 2026, 8:00:00 pm Market Open.

287 watching

Investor Insights

Jun 14, 2026, 12:00 am

This summary was created by AI, based on 43 opinions in the last 12 months.

UnitedHealth Group Inc (UNH-N) has faced considerable challenges over the past year, reflected in its declining stock price and regulatory scrutiny. Experts note that while the company is fundamentally strong with significant vertical integration in the U.S. healthcare system, it has been impacted by rising medical costs, regulatory pressures, and changes in Medicare reimbursement rates. The new CEO’s leadership is viewed as a positive factor that could guide the company through its current difficulties, but many analysts express caution due to the speculative nature of recent issues and the stock's volatility. Some believe the downturn creates buying opportunities, suggesting that long-term growth may be achievable if operational concerns are resolved. Overall, the sentiment is mixed, with a few experts optimistic about potential recovery while others advise caution until more clarity emerges.

Consensus

Cautious

Valuation

Undervalued

Similar

Cvs, CVS

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Oct 11/22, Up 9%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with UNH is progressing well. To remain disciplined, we recommend trailing up the stop to $500.

Wealthica Track your Stocks in your Watch List

BUY

Its Optum network is picking up steam and it's a stable cash flow generator.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly This defensive holding, UNH, is the largest managed care organization in the US, providing health care plans, pharmacy and analytics services. Recently reported earnings beat analyst expectations and support a 25% ROE. Cash reserves are growing, while stock is being repurchased. We recommend placing a stop-loss at $450, looking to achieve $590 -- upside potential of 16%. Yield 0% (Analysts’ price target is $590.00)

BUY

Healthcare offers both growth and defence. Their valuation remains reasonable and they have pricing power. AbbVie and Merck (his favourite) are also in this group. XLV is down only 12% vs. S&P down 24%.

COMMENT

Will it be affected by a Republican majority? One of the top performers in the S&P for a number of years. Among its peers, you can find other opportunities, equally successful, with less risk from a lower multiple. No political risk either way, as 70% of Americans are happy with their healthcare. See his Top Picks.

TOP PICK

Healthcare gives you the combination of defence and offence. Largest managed care provider in the US. Medical insurance, pharma benefits, and healthcare services create a strong value proposition to its customers. This will lead to steadily and reliable sales. Last quarter, easily beat expectations and raised earnings guidance for the full year. Earnings growth should top 12% over the next few years. Yield is 1.26%, will grow over time. (Analysts’ price target is $579.00)

BUY

This one has many major components, and all are growing nicely. Growth expected at 15% this year and next. Small dividend, growing double digits. Ultimately, legislative is supportive of these companies. Great performer in a tough market. He'd buy here, great risk/reward. Though if the market recovers quickly, it may not outperform in the near term.

BUY

A go-to name, core holding. Because it's the largest in the US, it won't get caught offside by upcoming regulatory changes, the way a smaller company would. Pretty consistent grower at 15-20% per year.

Wealthica Track your Stocks in your Watch List

BUY

Healthcare is his biggest sector. HC is seeing the classic shift to defensives as inflation peaks. Also, HC trades at only 18x while utilities and staples trade at 21x, so it's the cheapest defensive. He owns Pfizer, UNH and Regeneron. UNH's revenue and EPS beat recently. Healthcare has so many tailwinds, including again demographics. He likes preventative healthcare and UNH's position here. HC is fine in the late cycle. There's still to the upside here.

BUY

They report Friday and should have a great quarter, because Covid isn't as threatening as before. There is some cyclicality. If there are alot of layoffs, their numbers can weaken, but he doesn't see that now. Otherwise, keep buying, though he prefers the cheaper Humana.

PAST TOP PICK

(A Top Pick Jun 24/21, Up 27%) Adding to it. Is American's largest healthcare insurer and healthcare services. This synergy is great for customers. Also, healthcare offers defense as well as growth. Chart is trending upwards as the market goes down.

PAST TOP PICK

(A Top Pick Oct 20/20, Up 52%) Great business. Dominant player in managed care. GARP. Executing exceptionally well, consistent.

COMMENT

It beat two weeks ago, but it has struggled since then, because markets won't pay for future earnings. Not UNH's fault.

BUY

Healthcare has historically been a top sector after a yield curve inversion, when people get defensive. UNH dominates in commercial health, Medicare and Medicaid.

Unspecified

Has owned for many years. It is the best play in managed health care and helps payers and payees be more efficient and lower health care costs. Acquires and tucks in acquisitions. Highly innovative and very well managed. Maybe trading a bit on the rich side.

Showing 136 to 150 of 285 entries

Most Recent Experts

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Gordon Reid

GoodReid Investment Counsel

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

UnitedHealth Group Inc (UNH)

Unlock this Panic-proof Portfolio opinion with Stockchase Premium